SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Ionis Pharmaceuticals Inc – ‘10-K’ for 12/31/17 – ‘EX-10.4’

On:  Wednesday, 2/28/18, at 4:26pm ET   ·   For:  12/31/17   ·   Accession #:  874015-18-47   ·   File #:  0-19125

Previous ‘10-K’:  ‘10-K’ on 3/1/17 for 12/31/16   ·   Next:  ‘10-K’ on 3/1/19 for 12/31/18   ·   Latest:  ‘10-K’ on 2/21/24 for 12/31/23   ·   6 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/28/18  Ionis Pharmaceuticals Inc         10-K       12/31/17  109:18M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Ionis Pharmaceuticals Inc 10-K 12-31-2017           HTML   1.44M 
 2: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML    101K 
                -- exhibit3_1                                                    
 3: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     74K 
 4: EX-4.2      Instrument Defining the Rights of Security Holders  HTML     40K 
                -- exhibit4_2                                                    
 6: EX-10.10    Material Contract -- exhibit10_10                   HTML    985K 
 7: EX-10.17    Material Contract -- exhibit10_17                   HTML    669K 
 5: EX-10.4     Material Contract -- exhibit10_4                    HTML     62K 
 8: EX-21.1     Subsidiaries List -- exhibit21_1                    HTML     31K 
 9: EX-23.1     Consent of Experts or Counsel -- exhibit23_1        HTML     35K 
10: EX-31.1     Certification -- §302 - SOA'02 -- exhibit31_1       HTML     40K 
11: EX-31.2     Certification -- §302 - SOA'02 -- exhibit31_2       HTML     40K 
12: EX-32       Certification -- §906 - SOA'02 -- exhibit32_1       HTML     35K 
19: R1          Document and Entity Information                     HTML     60K 
20: R2          Consolidated Balance Sheets                         HTML    119K 
21: R3          Consolidated Balance Sheets (Parenthetical)         HTML     49K 
22: R4          Consolidated Statements of Operations               HTML    100K 
23: R5          Consolidated Statements of Comprehensive Loss       HTML     55K 
24: R6          Consolidated Statements of Stockholders' Equity     HTML    105K 
25: R7          Consolidated Statements of Stockholders' Equity     HTML     39K 
                (Parenthetical)                                                  
26: R8          Consolidated Statements of Cash Flows               HTML    163K 
27: R9          Consolidated Statements of Cash Flows               HTML     39K 
                (Parenthetical)                                                  
28: R10         Organization and Significant Accounting Policies    HTML    240K 
29: R11         Investments                                         HTML    143K 
30: R12         Long-Term Obligations and Commitments               HTML     90K 
31: R13         Stockholders' Equity                                HTML    116K 
32: R14         Income Taxes                                        HTML    159K 
33: R15         Collaborative Arrangements and Licensing            HTML    119K 
                Agreements                                                       
34: R16         Segment Information and Concentration of Business   HTML    122K 
                Risk                                                             
35: R17         Employment Benefits                                 HTML     35K 
36: R18         Legal Proceedings                                   HTML     37K 
37: R19         Quarterly Financial Data (Unaudited)                HTML    161K 
38: R20         Organization and Significant Accounting Policies    HTML    283K 
                (Policies)                                                       
39: R21         Organization and Significant Accounting Policies    HTML    167K 
                (Tables)                                                         
40: R22         Investments (Tables)                                HTML    144K 
41: R23         Long-Term Obligations and Commitments (Tables)      HTML     89K 
42: R24         Stockholders' Equity (Tables)                       HTML    107K 
43: R25         Income Taxes (Tables)                               HTML    161K 
44: R26         Segment Information and Concentration of Business   HTML    123K 
                Risk (Tables)                                                    
45: R27         Quarterly Financial Data (Unaudited) (Tables)       HTML    161K 
46: R28         Organization and Significant Accounting Policies,   HTML     36K 
                Basis of Presentation (Details)                                  
47: R29         Organization and Significant Accounting Policies,   HTML    118K 
                Basic and Diluted Net Income (Loss) per Share                    
                (Details)                                                        
48: R30         Organization and Significant Accounting Policies,   HTML    118K 
                Revenue Recognition (Details)                                    
49: R31         Organization and Significant Accounting Policies,   HTML     66K 
                Research, Development and Patent Expenses                        
                (Details)                                                        
50: R32         Organization and Significant Accounting Policies,   HTML     42K 
                Accrued Liabilities (Details)                                    
51: R33         Organization and Significant Accounting Policies,   HTML     50K 
                Noncontrolling Interest in Akcea Therapeutics,                   
                Inc. (Details)                                                   
52: R34         Organization and Significant Accounting Policies,   HTML     36K 
                Cash, Cash Equivalents and Short-Term Investments                
                (Details)                                                        
53: R35         Organization and Significant Accounting Policies,   HTML     38K 
                Inventory Valuation (Details)                                    
54: R36         Organization and Significant Accounting Policies,   HTML     69K 
                Property, Plant and Equipment (Details)                          
55: R37         Organization and Significant Accounting Policies,   HTML     35K 
                Long-Lived Assets (Details)                                      
56: R38         Organization and Significant Accounting Policies,   HTML     35K 
                Stock-based Compensation Expense (Details)                       
57: R39         Organization and Significant Accounting Policies,   HTML     57K 
                Accumulated Other Comprehensive Income (Loss)                    
                (Details)                                                        
58: R40         Organization and Significant Accounting Policies,   HTML     39K 
                Convertible Debt (Details)                                       
59: R41         Organization and Significant Accounting Policies,   HTML     38K 
                Segment Information (Details)                                    
60: R42         Organization and Significant Accounting Policies,   HTML     89K 
                Fair Value Measurements on a Recurring Basis                     
                (Details)                                                        
61: R43         Organization and Significant Accounting Policies,   HTML     49K 
                Fair Value Measurements - Novartis Future Stock                  
                Purchase (Details)                                               
62: R44         Organization and Significant Accounting Policies,   HTML     38K 
                Income Taxes (Details)                                           
63: R45         Organization and Significant Accounting Policies,   HTML     62K 
                Impact of Recently Issued Accounting Standards                   
                (Details)                                                        
64: R46         Investments, Contract Maturity of                   HTML     56K 
                Available-for-Sale Securities (Details)                          
65: R47         Investments, Summary of Investments (Details)       HTML    107K 
66: R48         Investments, Investments Temporarily Impaired       HTML     68K 
                (Details)                                                        
67: R49         Long-Term Obligations and Commitments, Long-Term    HTML     49K 
                Obligations (Details)                                            
68: R50         Long-Term Obligations and Commitments, Convertible  HTML    102K 
                Notes (Details)                                                  
69: R51         Long-Term Obligations and Commitments, Financing    HTML     57K 
                Arrangements (Details)                                           
70: R52         Long-Term Obligations and Commitments, Research     HTML     50K 
                and Development and Manufacturing Facilities                     
                (Details)                                                        
71: R53         Long-Term Obligations and Commitments, Maturity     HTML     59K 
                Schedules (Details)                                              
72: R54         Long-Term Obligations and Commitments, Operating    HTML     60K 
                Leases (Details)                                                 
73: R55         Stockholders' Equity, Preferred and Common Stock    HTML     63K 
                (Details)                                                        
74: R56         Stockholders' Equity, Stock Plans (Details)         HTML    105K 
75: R57         Stockholders' Equity, Stock Option Activity         HTML     91K 
                (Details)                                                        
76: R58         Stockholders' Equity, Restricted Stock Unit         HTML     66K 
                Activity (Details)                                               
77: R59         Stockholders' Equity, Stock-based Compensation      HTML     42K 
                Expense (Details)                                                
78: R60         Stockholders' Equity, Stock-based Valuation         HTML     51K 
                Information (Details)                                            
79: R61         Income Taxes, Loss Before Income Tax (Benefit)      HTML     40K 
                Expense (Details)                                                
80: R62         Income Taxes, Income Tax (Benefit) Expense          HTML     57K 
                (Details)                                                        
81: R63         Income Taxes, Reconciliation of Statutory to        HTML    112K 
                Effective Tax Rate (Details)                                     
82: R64         Income Taxes, Deferred Tax Assets and Liabilities   HTML     68K 
                (Details)                                                        
83: R65         Income Taxes, Tax Credit Carryforwards (Details)    HTML     57K 
84: R66         Income Taxes, Gross Unrecognized Tax Benefits       HTML     47K 
                (Details)                                                        
85: R67         Collaborative Arrangements and Licensing            HTML    102K 
                Agreements, AstraZeneca (Details)                                
86: R68         Collaborative Arrangements and Licensing            HTML    132K 
                Agreements, Biogen (Details)                                     
87: R69         Collaborative Arrangements and Licensing            HTML     72K 
                Agreements, Bayer (Details)                                      
88: R70         Collaborative Arrangements and Licensing            HTML     69K 
                Agreements, GSK (Details)                                        
89: R71         Collaborative Arrangements and Licensing            HTML     72K 
                Agreements, Janssen Biotech, Inc. (Details)                      
90: R72         Collaborative Arrangements and Licensing            HTML    115K 
                Agreements, Novartis (Details)                                   
91: R73         Collaborative Arrangements and Licensing            HTML     78K 
                Agreements, Roche (Details)                                      
92: R74         Collaborative Arrangements and Licensing            HTML     52K 
                Agreements, Achaogen, Inc. (Details)                             
93: R75         Collaborative Arrangements and Licensing            HTML     67K 
                Agreements, Alnylam Pharmaceuticals, Inc.                        
                (Details)                                                        
94: R76         Collaborative Arrangements and Licensing            HTML     46K 
                Agreements, Antisense Therapeutics Limited                       
                (Details)                                                        
95: R77         Collaborative Arrangements and Licensing            HTML     53K 
                Agreements, Atlantic Pharmaceuticals Limited                     
                (Details)                                                        
96: R78         Collaborative Arrangements and Licensing            HTML     52K 
                Agreements, Dynacure, SAS (Details)                              
97: R79         Collaborative Arrangements and Licensing            HTML     48K 
                Agreements, Regulus Therapeutics Inc. (Details)                  
98: R80         Collaborative Arrangements and Licensing            HTML     63K 
                Agreements, Suzhou Ribo Life Science Co., Ltd.                   
                (Details)                                                        
99: R81         Collaborative Arrangements and Licensing            HTML     35K 
                Agreements, The University of Texas MD Anderson                  
                Cancer Center (Details)                                          
100: R82         Collaborative Arrangements and Licensing            HTML     64K  
                Agreements, External Project Funding (Details)                   
101: R83         Collaborative Arrangements and Licensing            HTML     41K  
                Agreements, In-Licensing Agreements (Details)                    
102: R84         Segment Information and Concentration of Business   HTML     93K  
                Risk, Segment Information (Details)                              
103: R85         Segment Information and Concentration of Business   HTML     57K  
                Risk, Revenue from Significant Partners (Details)                
104: R86         Employment Benefits (Details)                       HTML     38K  
105: R87         Legal Proceedings (Details)                         HTML     40K  
106: R88         Quarterly Financial Data (Unaudited) (Details)      HTML    141K  
108: XML         IDEA XML File -- Filing Summary                      XML    195K  
107: EXCEL       IDEA Workbook of Financial Reports                  XLSX    148K  
13: EX-101.INS  XBRL Instance -- ions-20171231                       XML   4.14M 
15: EX-101.CAL  XBRL Calculations -- ions-20171231_cal               XML    326K 
16: EX-101.DEF  XBRL Definitions -- ions-20171231_def                XML   1.60M 
17: EX-101.LAB  XBRL Labels -- ions-20171231_lab                     XML   3.32M 
18: EX-101.PRE  XBRL Presentations -- ions-20171231_pre              XML   2.12M 
14: EX-101.SCH  XBRL Schema -- ions-20171231                         XSD    307K 
109: ZIP         XBRL Zipped Folder -- 0000874015-18-000047-xbrl      Zip    373K  


‘EX-10.4’   —   Material Contract — exhibit10_4


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 

Exhibit 10.4
 
IONIS PHARMACEUTICALS, INC.

EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS AGREEMENT

In consideration of my employment or continued employment by Ionis Pharmaceuticals, Inc., (the “Company”), and the compensation now and hereafter paid to me, I hereby agree as follows:

1.    Recognition of Company’s Rights; Nondisclosure.  At all times during the term of my employment and thereafter, I will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Company’s Confidential Information (defined below), except as such disclosure, use or publication may be required by the Company in connection with my work for the Company, or unless an officer of the Company expressly authorizes such in writing. I will not make any permitted disclosure, use or publication unless such disclosure, use or publication is in strict compliance with the Company’s publication and presentation clearance policy. I will not export, directly or indirectly, any Company products, any direct product thereof, or any related technical data in violation of the United States Department of Commerce’s Export Administration Regulations.

The term “Confidential Information” will mean trade secrets, confidential knowledge, data or any other proprietary information of the Company.  By way of illustration but not limitation, “Confidential Information” includes (a) inventions, mask works, trade secrets, ideas, processes, formulas, source and object codes, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques (hereinafter collectively referred to as “Inventions”); and (b) information regarding plans for research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; as well as information regarding the skills and compensation of other employees of the Company.

2.    Third Party Information.  I understand, in addition, that the Company has received and in the future will receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes.  During the term of my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose (except as required to be disclosed in connection with my work for the Company) Third Party Information unless expressly authorized by an officer of the Company in writing.  I will not make any permitted disclosures unless such disclosure is in strict compliance with the Company’s publication and presentation clearance policy.

3.     Assignment of Inventions

3.1      Assignment
(a)       I hereby assign to the Company all my right, title and interest throughout the world in and to any and all Inventions (and all patent rights, copyrights, and all other rights in connection therewith, hereinafter referred to as “Proprietary Rights”) whether or not patentable or registrable under patent, copyright, trademark or similar statutes (together with the goodwill associated therewith), made or conceived or reduced to practice or learned by me, either alone or jointly with others, during the period of my employment with the Company or within 1 year after termination of my employment, which relate to any Company Invention or to any work performed by me while I was employed by the Company. Inventions assigned to the Company by this Paragraph 3 are hereinafter referred to as “Company Inventions.”  I agree, upon request, to execute, verify and deliver assignments of such Proprietary Rights to the Company or its designee.
 
1

(b)       If I am employed by the Company in the State of California, I recognize that this Agreement does not require assignment of any invention which qualifies fully for protection under Section 2870 of the California Labor Code (hereinafter “Section 2870”), which provides as follows:

(i)    Any provision in an employment agreement which provides that an employee will assign, or offer to assign, any of his or her rights in an invention to his or her employer will not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:

(1)   Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer.

(2)   Result from any work performed by the employee for the employer.

(ii)   To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (i), the provision is against the public policy of this state and is unenforceable.

3.2      Government.  I also agree to assign all my right, title and interest in and to any and all Company Inventions to the United States of America, if such is required to be assigned by a contract between the Company and United States of America or any of its agencies.
 
3.3      Works for Hire.  I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment as well as those works made by me within 1 year after termination of my employment which relate to any work made by me while I was employed by the Company and which are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act (17 U.S.C., Section 101).

4.    Enforcement of Proprietary Rights.  I will assist the Company in every proper way to obtain and from time to time enforce United States and foreign Proprietary Rights relating to Company Inventions in any and all countries.  My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my employment, but the Company will compensate me at a reasonable rate after my termination for the time actually spent by me if the Company requests such assistance.

I hereby waive and transfer to the Company, any and all claims, of any nature whatsoever, which I now or may hereafter have, for infringement of any Proprietary Rights assigned hereunder to the Company.

5.     Obligation to Keep Company Informed.  During the period of my employment, I will promptly disclose all Company Inventions to the Company fully and in writing and will hold such Company Inventions in trust for the sole right and benefit of the Company.  In addition, after termination of my employment, I will disclose all patent applications filed by me within a year after termination of employment which relate to any Company Invention or to any work performed by me while I was employed by Company.
 
2

6.    Prior Inventions.  Inventions, if any, patented or unpatented, which I made prior to the commencement of my employment with the Company are excluded from the scope of this Agreement.  To preclude any possible uncertainty, I have set forth in Exhibit A attached hereto a complete list of all Inventions that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of my employment with the Company, that I consider to be my property or the property of third parties and that I wish to have excluded from the scope of this Agreement.  If disclosure of any such Invention on Exhibit A would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Inventions in Exhibit A but am to inform the Company that all such Inventions have not been listed for that reason.

7.     Additional Activities.

(a)      I agree that during the period of my employment by the Company I will not, without the Company’s express written consent, engage in any employment or business activity other than for the Company.  Additionally, during the period of my employment by the Company and for 1 year after the date of termination of my employment with the Company I will not induce any employee of the Company to leave the employ of the Company.
 
(b)      I acknowledge that the Company has developed, through an extensive acquisition process, valuable information regarding actual or prospective partners, licensors, licensees, clients, customers and accounts of the Company (“Trade Secret Information”).  I further acknowledge that my use of such Trade Secret Information after the termination of my employment would cause the Company irreparable harm.  Therefore, I agree that I will not use Trade Secret Information to solicit the business relationship or patronage of any of the actual or prospective partners, licensors, licensees, clients, customers or accounts of the Company.

8.     No Improper Use of Materials.  During my employment by the Company I will not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of the Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.

9.     No Conflicting Obligation.  I represent that my performance (a) of all the terms of this Agreement and (b) as an employee of the Company, does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by the Company.  I have not entered into, and I will not enter into, any agreement that conflicts with this Agreement.

10.  Return of Company Documents.  When I leave the employ of the Company, I will deliver to the Company any and all laboratory notebooks, conception notebooks, drawings, notes, memoranda, specifications, devices, formulas, molecules, cells, storage media, including software and documents, including any computer printouts, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of the Company.  I further agree that any property situated on the Company’s premises and owned by the Company including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice.  Prior to leaving, I will cooperate with the Company in completing and signing the Company’s termination statement for technical and management personnel.
 
3

11.  Legal and Equitable Remedies.  Because my services are personal and unique and because I may have access to and become acquainted with the Confidential Information of the Company, the Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond, without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement.

12.  Notices.  Any notices required or permitted hereunder will be given to me at the address specified below or at such other address as I will specify in writing.  Such notice will be deemed given upon personal delivery to the appropriate address, or by facsimile transmission (receipt verified and with confirmation copy following by another permitted method), telexed, sent by express courier service, or, if sent by certified or registered mail, three days after the date of mailing.

13.  General Provisions

13.1    Governing Law.  This Agreement will be governed by and construed according to the laws of the State of California.
 
13.2    Entire Agreement.  This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior discussions between us.  No modification or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by both parties.  Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.  As used in this Agreement, the period of my employment includes any time during which I may be retained by the Company as a consultant.
 
13.3    Severability.  If any of the provisions in this Agreement are deemed unenforceable by law, then the remaining provisions will continue in full force and effect.
 
13.4    Successors and Assigns.  This Agreement will be binding upon my heirs, executors, administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns.
 
13.5    Survival.  The provisions of this Agreement will survive the termination of my employment and the assignment of this Agreement by the Company to any successor in interest or other assignee.
 
13.6    Employment.  I agree and understand that nothing in this Agreement will confer any right with respect to continuation of employment by the Company, nor will it interfere in any way with my right or the Company’s right to terminate my employment at any time, with or without cause.
 
13.7    Waiver.  No waiver by the Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach.  No waiver by the Company of any right under this Agreement will be construed as a waiver of any other right.  The Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.
 
4

This Agreement will be effective as of the first day of my employment with the Company, namely:  _________________,  20____.

I UNDERSTAND THAT THIS AGREEMENT AFFECTS MY RIGHTS TO INVENTIONS I MAKE DURING MY EMPLOYMENT, AND RESTRICTS MY RIGHT TO DISCLOSE OR USE THE COMPANY’S CONFIDENTIAL INFORMATION DURING OR SUBSEQUENT TO MY EMPLOYMENT.

I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS.  I HAVE COMPLETELY FILLED OUT EXHIBIT A TO THIS AGREEMENT.

Dated:
       
       
Signature
         
       
Name of Employee
         
 
Address
   
         
         

ACCEPTED AND AGREED TO:

Ionis Pharmaceuticals, Inc.

By:
   
   
Signature
   
Shannon L. Devers
   
Printed Name
   
Vice President, Human Resources
   
Title
 
5

EXHIBIT A

IONIS PHARMACEUTICALS, INC.
2855 Gazelle Court
Carlsbad, California 92010

1.  The following is a complete list of all inventions or improvements relevant to the subject matter of my employment by Ionis Pharmaceuticals, Inc. (the “Company”) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company:

[   ]  No inventions or improvements.          [   ]  See below:

 
 
 

[  ]  Due to confidentiality agreements with prior employer, I cannot disclose certain inventions that would otherwise be included on the above-described list.

[   ]  Additional sheets attached.

2.  I propose to bring to my employment the following devices, materials and documents of a former employer or other person to whom I have an obligation of confidentiality that are not generally available to the public, which materials and documents may be used in my employment pursuant to the express written authorization of my former employer or such other person (a copy of which is attached hereto):

[   ]  No material          [   ]  See below:

 
 
 

[   ]  Additional sheets attached.

Date:
     
       
 
Employee Signature
   
 
 
6


6 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/21/24  Ionis Pharmaceuticals Inc.        10-K       12/31/23  103:18M
11/24/23  Ionis Pharmaceuticals Inc.        S-3ASR     11/24/23    4:299K                                   Broadridge Fin’l So… Inc
 2/22/23  Ionis Pharmaceuticals Inc.        10-K       12/31/22  110:25M
 2/25/22  Ionis Pharmaceuticals Inc.        10-K       12/31/21  106:22M
 2/24/21  Ionis Pharmaceuticals Inc.        10-K       12/31/20  111:23M
 8/07/20  Ionis Pharmaceuticals Inc.        S-3ASR      8/10/20    3:275K                                   Broadridge Fin’l So… Inc
Top
Filing Submission 0000874015-18-000047   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., May 12, 7:20:42.1am ET